BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 27
• 30
• 31

• Business

  OvaScience CEO Michelle Dipp, M.D., Ph.D., Joins Biotechnology Industry Organization’s Board Of Directors

  December 9, 2013

   · 

  1 min read
• Drug Development

  Enzymotec Announces Publication Acceptance Of Clinical Study Results On Usage Of Vayacog® In Non-Demented Elderly

  December 9, 2013

   · 

  1 min read
• Drug Development

  New Alnylam Pharmaceuticals Pre-Clinical Results On ALN-CC5, An RNAi Therapeutic Targeting Complement Component C5 For The Treatment Of Complement-Mediated Diseases, Demonstrate Up To 98% Serum C5 Knockdown And Up To 94% Inhibition Of Hemolytic Activity I

  December 9, 2013

   · 

  1 min read
• Drug Development

  Cyclacel Pharmaceuticals, Inc. Reports New Phase 2 Data Of Sapacitabine For MDS At American Society of Hematology

  December 9, 2013

   · 

  1 min read
• Seattle Genetics, Inc. And Takeda Pharmaceutical Co. Ltd. Highlight Long-term Follow-up Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Clinical Trials

  December 9, 2013

   · 

  1 min read
• Drug Development

  Chelsea Therapeutics, Inc. Announces First Patient Dosed In NORTHERA™ (Droxidopa) Study 401 For The Treatment Of Symptomatic NOH

  December 9, 2013

   · 

  1 min read
• Genetown

  Karyopharm Therapeutics Presents Promising Data For Selinexor, An Oral, First-In-Class Selective Inhibitors Of Nuclear Export (SINE) Compound, In Hematologic Malignancies At 2013 American Society of Hematology Annual Meeting

  December 9, 2013

   · 

  1 min read
• BioCapital

  Synthetic Biologics, Inc.’ Webcast Conference Call Set For 9:00 A.M. EST This Morning, December 9TH

  December 9, 2013

   · 

  8 min read
• Drug Development

  Biogen Idec, Inc. (Massachusetts) And Swedish Orphan Biovitrum Release: New Phase 3 Data Confirm Long-Lasting Characteristics Of ALPROLIX™ And ELOCTATE™ Across Multiple Hemophilia Populations

  December 9, 2013

   · 

  1 min read
• BioCapital

  MaxCyte, Inc. Presents Data On Stable Cell Line Generation And Rapid, High Titer Production Of Antibodies And Proteins Using Flow Electroporation

  December 9, 2013

   · 

  1 min read